Plasma fibrinogen levels have been identified as an important risk factor for cardiovascular diseases. Among the few compounds known to lower circulating fibrinogen levels in humans are certain fibrates. We have studied the regulation of fibrinogen gene expression by fibrates in rodents. Treatment of adult male rats with fenofibrate (0.5% [wt/wt] in the diet) for 7 days decreased hepatic Aα-, Bβ-, and γ-chain mRNA levels to 52% ± 7%, 46% ± 8%, and 81% ± 19% of control values, respectively. In parallel, plasma fibrinogen concentrations were decreased to 63% ± 7% of controls. The suppression of fibrinogen expression was dose-dependent and was already evident after 1 day at the highest dose of fenofibrate tested (0.5% [wt/wt]). Nuclear run-on ...
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic triglyceride accumulation, ran...
An elevated plasma fibrinogen level is increasingly accepted as an independent risk indicator of car...
Fenofibrate (FF) lowers plasma triglycerides via PPARα activation. Here, we analyzed lipidomic chang...
Fibrates are used to lower plasma triglycerides and cholesterol levels in hyperlipidemic patients. I...
Fibrinogen is a coagulation factor and an acute phase reactant up-regulated by inflammatory cytokine...
Fibrates are widely used drugs in hyperlipidemic disorders. In addition to lowering serum triglyceri...
The influence of different fibrates on apolipoprotein metabolism was investigated. Administration of...
Hepatic triacylglycerol (TAG) homeostasis is maintained by carefully regulated balance between its s...
Abstract—Treatment with fibrates, a widely used class of lipid-modifying agents, results in a substa...
Mice have been used widely to define the mechanism of action of fibric acid derivatives. The fibrate...
International audiencePeroxisome proliferator-activated receptor alpha (PPARa) activation by fibrate...
The molecular mechanism by which hypolipidemic fibrates and antidiabetic thiazolidinediones exert th...
Fibrates are hypolipidemic drugs that affect the expression of genes involved in lipid metabolism by...
In view of the evidence linking plasma high density lipopro-tein (HDL)-cholesterol levels to a prote...
The hypolipidemic fibrates and antidiabetic thiazolidinediones display potent triglyceride-lowering ...
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic triglyceride accumulation, ran...
An elevated plasma fibrinogen level is increasingly accepted as an independent risk indicator of car...
Fenofibrate (FF) lowers plasma triglycerides via PPARα activation. Here, we analyzed lipidomic chang...
Fibrates are used to lower plasma triglycerides and cholesterol levels in hyperlipidemic patients. I...
Fibrinogen is a coagulation factor and an acute phase reactant up-regulated by inflammatory cytokine...
Fibrates are widely used drugs in hyperlipidemic disorders. In addition to lowering serum triglyceri...
The influence of different fibrates on apolipoprotein metabolism was investigated. Administration of...
Hepatic triacylglycerol (TAG) homeostasis is maintained by carefully regulated balance between its s...
Abstract—Treatment with fibrates, a widely used class of lipid-modifying agents, results in a substa...
Mice have been used widely to define the mechanism of action of fibric acid derivatives. The fibrate...
International audiencePeroxisome proliferator-activated receptor alpha (PPARa) activation by fibrate...
The molecular mechanism by which hypolipidemic fibrates and antidiabetic thiazolidinediones exert th...
Fibrates are hypolipidemic drugs that affect the expression of genes involved in lipid metabolism by...
In view of the evidence linking plasma high density lipopro-tein (HDL)-cholesterol levels to a prote...
The hypolipidemic fibrates and antidiabetic thiazolidinediones display potent triglyceride-lowering ...
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic triglyceride accumulation, ran...
An elevated plasma fibrinogen level is increasingly accepted as an independent risk indicator of car...
Fenofibrate (FF) lowers plasma triglycerides via PPARα activation. Here, we analyzed lipidomic chang...